ABSTRACT To characterize the potential of nifedipine in the therapy of unstable angina pectoris we implemented a blinded, randomly assigned, titrated schedule of conventional therapy (propranolol, if not contraindicated, and isosorbide dinitrate) or nifedipine for 14 days in 126 patients hospitalized in a coronary care unit for ischemic chest pain of less than 45 min duration. There were no significant differences between conventionally and nifedipine-treated patients with regard to (1) the time to relief of pain as judged by life table analysis, (2) the decrease in anginal attacks per 24 hr from day 0 to day 2 ( -2.5 + 0.4 for conventional therapy vs; -2.8 + 0.3 for nifedipine), (3) the decrease in the number of nitroglycerin tablets consumed per 24 hr ( -2.0 ± 0.5 for conventional vs -2.1 ± 0.4 for nifedipine therapy), (4) the percentage of patients requiring morphine on day 1 (1 3% for conventional vs 21 % for nifedipine therapy), or (5) the percentage of patients who developed infarction (1 4% in both groups). Among the 27 patients who did not respond to initial conventional (n = 13) or nifedipine therapy (n = 14), five in each group became pain free when the opposite therapy (either nifedipine or conventional therapy) was added. In the subgroup of 67 patients who were receiving propranolol before randomization, addition of nifedipine was more effective in controlling pain than was an increase in conventional therapy (p = .026). In the subgroup of 59 patients not receiving prior propranolol, initiation of conventional therapy produced more rapid pain relief than initiation of nifedipine therapy alone (p < .001), which tended to increase heart rate. Thus, for the study population as a whole therapy with nifedipine alone was equivalent to conventional therapy for unstable angina, although this overall equivalence may result from a combination of superiority of nifedipine therapy in patients previously receiving ,/-blocker therapy and superiority of /3-blocker therapy in patients not previously receiving ,3-blockers. Circulation 69, No. 4, 728-739, 1984. UNSTABLE ANGINA, a syndrome intermediate in severity between stable angina pectoris and acute myocardial infarction, is well recognized. Heberden,' in his classic description of angina pectoris, noted that in some cases the pain occurred in patients at rest. Her- 
and as a result it is now accepted practice to begin treatment with medical therapy and to proceed to CABG only in those patients whose conditions are resistant to intensive medical management.
The keystone of conventional medical therapy for the control of unstable angina pectoris is a combination of nitrate therapy and, if not contraindicated, fl-blockade.9 '-However, the objective evidence supporting the use of these drugs is surprisingly meager and is not based on results of randomized, double-blind, placebo-controlled studies. 10.1t To complicate matters, it has been suggested that in many patients bed rest alone is adequate therapy,'2 that anticoagulants may prevent progression to transmural infarction,'3 and that /3-blockade may actually exacerbate coronary artery spasm, 14, 15 which is now considered a more frequent cause of unstable angina than previously recognized. 16 The widespread availability of calcium-channel blocking drugs has added new promise, and new complexity, to the selection of proper medical therapy for unstable angina. i7, 1 ' These drugs are extremely effective against coronary artery spasm. 23 Nifedipine, the drug we investigated in this study, has been shown to be superior to placebo for therapy of stable angina pectoris24 and Prinzmetal's angina.22 23 Early uncontrolled studies suggest that nifedipine may relieve pain in many patients with unstable angina who do not respond to conventional therapy. 25 27 In a large group of patients with unstable angina, including patients with and without ST segment elevation during pain, nifedipine has been found to be superior to placebo for control of pain after the acute episode when added to conventional therapy. 28 The present study was undertaken to provide in a double-blind, randomized manner an estimation of the efficacy of initial therapy of unstable angina with the calcium-channel blocker nifedipine and to compare it with that of initial treatment with propranolol and/or nitrates, i.e., conventional therapy. The trial was begun in 1979 and conducted by investigators from six institutions (see Appendix). Primary end points were the control of anginal pain and the incidence of progression to myocardial infarction.
Methods
Patient selection. Over the 39 month course of the study, 1388 patients were screened for eligibility. All had been admitted to one of the four participating coronary care units (CCUs) and had experienced one or more episodes of pain of less than 45 min duration that were thought by the investigator to be caused by myocardial ischemia. A total of 682 patients was identified as fulfilling both of the following inclusion criteria:
(I) Pain considered characteristic of unstable angina pectoris Vol. 69, No. 4 , April 1984 within 24 hr of randomization. Unstable angina may have been present for any interval but no more than 24 hr could have elapsed between the last episode of pain and randomization, and no episode of pain within the previous 24 hr could have exceeded 45 min in duration. The pattern of angina could have been one of the following: (a) Progressive angina, i.e., progressive increases in intensity, frequency, duration, ease of provocation, or difficulty of relief with nitrates, either soon after the initial onset of angina pectoris or manifest as a change in the pattern of longstanding stable angina. (b) Angina at rest, including nocturnal angina.
(2) Either of the following markers of coronary artery disease: (a) Electrocardiographic (ECG) evidence of reversible myocardial ischemia in any lead of a standard 12-lead ECG with any attack of pain. This could have been either new or presumably new ST segment elevation or depression of at least 0.05 mV that had begun to return, or that had already returned, toward normal or a known baseline, or T waves that inverted and became isoelectric or began to resume their original polarity after cessation of the episode. (b) Documented coronary artery disease manifest by either prior myocardial infarction, or at least 70% luminal diameter narrowing of at least one coronary artery detected by a prior coronary angiogram.
Among the patients who satisfied the inclusion criteria, a total of 489 were excluded for the reasons listed in table 1, leaving 193 eligible patients of whom 133 were willing to particiate in the study.
After informed consent had been obtained, patients were assigned to group A (additional propranolol acceptable) or 24 sec, or second-or thirddegree atrioventricular block). The level of therapy was increased only if an episode of pain occurred after more than 2 hr had been allowed for absorption and distribution of the drug. Angina during the period of increase in dosage of the experimental drug was treated initially with sublingual nitroglycerin, in the dose and frequency deemed necessary by the treating physician. If nitroglycerin was ineffective, morphine was given. Thus, advances to higher levels of therapy were dictated by continuing anginal attacks.
The primary randomized comparison of the study was between conventional and nifedipine therapy at levels 1, 2, and 3, as shown in table 3. If angina recurred despite maximal conventional or nifedipine therapy at level 3, the alternative therapy was added in a graduated fashion (levels 4, 5, and 6). By the time patients reached level 6, they had received identical ther- apies (nitrates, propranolol, and nifedipine) despite differences in their initial random assignment in levels 1 to 3. Drugs were administered every 6 hr from randomization until the 14 day evaluation (even if myocardial infarction occurred after randomization) unless an adverse effect of therapy developed or CABG was performed.
Study organization. A standardized protocol for the study was developed by the investigators from the participating institutions listed in the Appendix. Core laboratories were established for the analysis of CK and ECG data. An external policy board reviewed the progress of the study at yearly intervals. Investigators were blinded to the results of the study, which were maintained by a data coordinating center at the Harvard Medical School.
Data collection and follow-up. Blood samples for determination of total CK and CK-MB for central analysis were drawn every 8 hr for 72 hr after randomization and then every 12 hr through the seventh day (or until discharge from the hospital). Twelve-lead ECGs were obtained daily for the first 3 days after randomization, and then every other day until the fourteenth day or until discharge from the hospital. All patients were evaluated by a physician 14 days after randomization, after which therapy with propranolol and/or isosorbide or nifedipine was discontinued and the patients' treatment assignments were unblinded. Vital status was determined by a telephone call 6 months after randomization.
Details of the present illness, the past medical history, and physical examination and routine laboratory test results were entered on standardized forms. Pulse and blood pressure determinations were recorded at baseline and at least once during each level of therapy.
Statistical methods. The Yates corrected chi-square test32 was used to compare the two treatment groups within groups A and B separately for all baseline characteristics other than the dose of [3-blocker. The patients were compared with respect to dose of /3-blockers by the two-sample t test31 after application of a logarithmic transformation to better normalize the underlying probability distributions. The Yates corrected chi-square test was used to compare the incidence of side effects in the two treatment groups within groups A and B, respectively. In those instances in which expected cell frequencies were <5, Fisher's exact test was used. 32 The log-rank method of life table analysis33 was used to compare the time to relief of pain for at least 48 hr during levels 1 to 3 of therapy between treatment groups, both overall' and within the subgroups of patients who did and did not receive prior fl-blockade. Similar analyses were performed comparing time to relief of pain in those with and without new ST segment elevation, and time to relief of pain in those with three-vessel disease vs those with 0, one-, or two-vessel disease among those undergoing coronary angiography. All other end points were analyzed with the use of either the Yates corrected chi-square test (or Fisher's exact test) for binary outcomes or the'twosample t test for continuous outcomes. Variations from mean values are expressed as SE.
Results
Study population. A total of 9994 patients was admitted to the four CCUs during the study; ofthese 1388 (14%) had pain characteristic of unstable angina and were screened for eligibility. Of these 682 met inclusion criteria ( Of the 133 patients participating (98 group A; 35 group B), four were identified by the CK core laboratory as having experienced a myocardial infarction immediately before randomization, and an additional three were found by the ECG core laboratory not to have met the ECG criteria. As stipulated by the protocol, data from these seven patients (six group A; one group B) were excluded from subsequent analysis, leaving a total of 126 eligible patients who took part in the randomization protocol (92 group A; 34 group B).
Baseline characteristics, adherence to protocol, and untoward effects. There were no significant differences between treatment groups within either group A or B in any of the baseline variables known to be related to prognosis (table 4). The distribution of patients with regard to type of unstable angina and type of ECG changes is presented in table 5. Data collection for the principal end points of the study (control of pain and occurrence of myocardial infarction within 2 weeks of randomization) was complete for all 126 eligible, randomized patients, including patients for whom experimental therapy was terminated before the 14 day evaluation or before relief of pain for 48 hr. Therapy at levels 1 to 3 was terminated prematurely in nine of 126 (7%) patients and therapy at levels 4 to 6 was terminated in an additional seven (6%) patients. The most frequent reasons for premature termination were hypotension in three and CABG in two patients. Premature unblinding occurred in nine of 126 (7%) patients. 'Angina more than 3 weeks before the qualifying episode. t'Angina < 3 weeks before the qualifying episode. In addition to the lack of difference in pain relief between conventionally and nifedipine-treated patients, there was no significant difference in the reduction in attacks of angina per 24 hr, the reduction in sublingual nitroglycerin use, or the percentage of patients requiring morphine for relief of pain during the 48 hr after randomization (table 7) .
There were, however, significant differences between conventional therapy and nifedipine when results were compared for subgroups of patients who did and those who did not receive /8-blockers before randomization. In the subgroup of 67 patients who were receiving prior ,3-blockade (average dose of propranolol, 115.1 ± 13.0 mg/day), which was continued as baseline therapy, an increase in /3-blockade and/ or addition of nitrates failed to control pain as rapidly as did treatment with nifedipine (figure 2; p = .026). The opposite result was observed in the subgroup of 59 patients who had not received /3-blockers before randomization; in these patients subsequent treatment with /3-blocker and/or nitrate therapy led to more rapid control of pain than did initiation of nifedipine treatment (figure 3; p < .001).
These differences in therapeutic response in the presence or absence of prerandomization propranolol were not reflected in other less sensitive indexes of anginal control. Thus, although prior treatment with propranolol was noted to influence the speed with which patients became pain free during levels 1 to 3 of therapy with nifedipine or conventional therapy when the method of life table analysis was used, no difference was noted in the percentage of patients who obtained relief of chest pain, a less sensitive end point. In addition, there was no difference between conventional therapy and nifedipine with regard to the reduction in attacks of angina per 24 hr, the reduction in nitroglycerin use, or the percentage of patients requiring morphine in either subgroup of patients receiving different prerandomization therapy.
For the study population as a whole there were no significant differences in time to relief of pain during levels 1 to 3 for the two treatment groups in subgroups with (n = 36) or without (n = 90) new ST segment elevation and in subgroups with (n -80) or without (n 46) angina at rest. Results in separate clinical units were consistent with the results for the entire study population.
Heart rate responses. There were no significant differences between treatment groups in mean heart rate at the time of randomization in either group A or in group B. In group A the administration of propranolol produced the expected slowing, while nifedipine therapy led to a significant increase in heart rate. The average of the highest heart rates observed during level 1 of therapy with propranolol and nitrates fell by 3.7 ± 1.6 beats/min to 76.0 ± 1.7 (p -.025), while therapy with nifedipine led to an increase of 5.1 ± 1.6 beats/ the fall in pressure with nitrates did not differ significantly from the fall with nifedipine.
Occurrence of myocardial infarction. There was no difference in the incidence of myocardial infarction with- (These patients do not include the four identified by the core laboratory as having experienced a myocardial infarction before randomization.) MB-CK infarct size index was similar (5.8 ± 1.8 vs 7.6 ± 2.2 MB-CK-geq/m2 for conventional and nifedipine therapy, respectively, NS). In addition, no significant differences were noted in the loss of R wave voltage in these patients with infarction. Mortality. In the 14 days after randomization, there were no deaths among those patients randomized to conventional therapy and four deaths among those initially randomized to nifedipine (NS, p = .13). Three of the four deaths occurred after level 3 had been passed, i.e., after propranolol and/or nitrate therapy had been added. In one of these patients, symptoms of infarction began during initial nifedipine therapy, but the patient died while receiving maintenance nitrate and propranolol 6 days after nifedipine had been discontinued. All four deaths resulted from a myocardial infarction that occurred after randomization and led to cardiogenic shock; three of these four patients had a history of a myocardial infarction before randomization.
From 2 weeks to 6 months after randomization, there were two deaths in the conventional therapy group and one in the nifedipine group, resulting in a 6 month mortality of two of 63 (3%) in the group receiving conventional therapy vs five of 63 (8%) in the group initially randomized to nifedipine (NS). Three of the five patients in the nifedipine group actually received propranolol and/or nitrates before their deaths.
Results of coronary arteriography. Although coronary arteriography was not required by the protocol, 53 (42%) of the patients underwent this procedure in the interval from 3 months before to 3 months after randomization. Significant coronary stenosis was defined as ?70% narrowing of the luminal diameter. Ten of the patients had no coronary stenosis, 14 than those with less severe coronary atherosclerosis.
Discussion
These findings indicate that ischemic pain in patients with unstable angina pectoris can be controlled as readily with nifedipine alone as with conventional medical therapy (,8-blockade and nitrates). Among the patients in the entire study population there were no significant differences between these two forms of therapy with respect to several indexes of the efficacy of medical therapy (e.g., time to pain relief, percentage of patients achieving pain relief, reduction in the number of attacks of pain per day, reduction in the amount of nitroglycerin required or in the number of patients requiring morphine therapy). Pain relief was achieved by level 3 therapy in 73% (46 of 63) of the patients randomly assigned to conventional therapy and in 70% (44 of 63) of the patients in the nifedipine group. As is generally the case for routine initial management of unstable angina pectoris, the results of coronary angiography were not used to guide selection of therapy. It is possible that different results could be obtained in patients in whom therapy is altered specifically to conform with the presence or absence of severe obstructive coronary disease, but such information is often unavailable for patients presenting with unstable angina.
The size of the study population was large enough (126 patients) to provide adequate power for detection of a clinically significant difference between the two regimens if such a difference existed. Specifically, this study had a 90% chance of detecting a significant difference between the two groups if the true rate of pain relief were 73% in the control population and either lower than 45% or greater than 94% in the nifedipinetreated population (assuming a two-sided significance test with a p value of .05).
Several important features of this study deserve mention. First, it is one of a limited number of randomized, double-blind evaluations of medical therapy for unstable angina pectoris. The rationale for medical therapy of unstable angina is based on extrapolations from randomized studies of stable angina, although the pathogenetic mechanisms of dynamic obstruction and/ or thrombosis may be more frequent in unstable angina. Second, the characteristics of the patients eligible to enroll in this study were rigorously defined. The lack of a universally accepted definition of unstable angina, as well as its variable natural history, have often produced confusion in comparison of results between randomized studies. Third, data are available for a subgroup of unstable angina patients with ST 736 segment depression and transient T wave changes during attacks, i.e., the subgroup that is most commonly seen in clinical practice. The effects of calcium-channel blockers have been well studied in the subgroup of patients with frequent episodes of pain at rest associated with ST segment elevation,' 24 but only a small amount of information is available regarding the response to calcium-channel blockers in patients with unstable angina with ST segment depression. The results in this subgroup did not differ from those observed in the entire study population.
Although the most general analysis of the data showed equivalence between nifedipine and conventional therapy, significant differences emerged from analysis of the patient subgroups of those who had and had not received previous /-blocker therapy. The latter was continued after randomization as background therapy. By definition, this level of /3-blockade had failed to control the unstable angina since patients still experienced episodes of pain that qualified them for the study. In such patients, initiation of nifedipine relieved pain more rapidly than did administration of additional propranolol and/or nitrates. In contrast, among patients not receiving a /3-blocker before randomizatiaon, initial treatment with propranolol and/or nitrates was superior to nifedipine. The heart rate responses to therapy in those who did and did not receive prior /3-blockade were compatible with a plausible mechanism for this differential effect. Nifedipine produced a greater increase in heart rate in patients who had not received prior propranolol than it did in patients already receiving /3-blockade. Conversely, conventional therapy produced a greater slowing of heart rate in patients who had not previously received propranolol than in those who had. Thus, in the patients who had not received prior propranolol, the change in heart rate with nifedipine therapy was 12.4 beats/min higher than with conventional therapy (p < .001). In contrast, in those who had received prior propranolol therapy, the change in heart rate with nifedipine therapy was only 3.3 beats/min higher than in those who received conventional therapy. This greater increase in heart rate and the resultant increase in myocardial oxygen demand when nifedipine was given to patients who had not received a /3-blocker would be expected to diminish its effectiveness.
Results in patients already receiving /S-blockade are consistent with the finding of Gerstenblith et al.28 that addition of nifedipine is superior to addition of placebo for the control of unstable angina in patients already treated with propranolol. Our results, however, indicate a greater benefit of nifedipine because it was supe-rior not only to placebo alone, but also to the addition of propranolol and/or nitrates in patients previously taking /3-blockers. The findings of the present study do not support the concern that propranolol, because of a tendency to enhance spasm,'4 is harmful to patients with unstable angina. Gerstenblith et al.28 speculated that the benefit of nifedipine observed in their study might have been even more marked if propranolol had not been administered concomitantly. However, in our study nifedipine seemed to be more effective when given against a background of /3-blockade than when given in its absence.
Although the findings in the subgroups receiving and not receiving prior /3-blockade are of interest, they must be interpreted with caution because this particular analysis was not planned before the start of the trial. In addition, other less sensitive end points of the trial, such as nitroglycerin use and number of anginal attacks per day, failed to show significant differences between these subgroups.
Twenty-seven of the 36 patients who failed to respond to the therapy to which they were initially assigned were treated with the addition of the alternate therapy (levels 4 to 6). The addition of the alternate therapy was accompanied by the control of pain in 37% (10/27) of the patients (five of 13 patients receiving additional propranolol and/or nitrate therapy, five of 14 receiving additional nifedipine). This finding, which is similar to that of other investigators for the addition of nifedipine,25-27 could be the result of the additional therapy but could also represent spontaneous cessation of unstable angina.'2 The data indicate, however, that regardless of which therapy is administered first, the combination of nifedipine with propranolol and nitrates (in association with standard care) resulted in control of unstable angina for at least 48 hr in 100 of 126 (79%) patients.
Although higher doses of nitrates have been proposed as therapy for unstable angina,34 the dosage used in this study (20 mg isosorbide dinitrate every 6 hr) was sufficient to produce headache in 30% of the patients receiving the drug. Headache was severe enough to require discontinuation of nitrates in four patients; in contrast, the nifedipine dose (30 mg every 6 hr), which was as effective as the nitrate dose in controlling pain, produced headache in only 5% of patients and in no instance was the headache severe enough to require discontinuation of therapy.
The incidence of myocardial infarction within 2 weeks of randomization, the second major end point of the study, was identical for patients initially randomized to conventional (14%) and to nifedipine (14%)
Vol. 69, No. 4, April 1984 therapies. This finding is similar to results obtained in other studies in which relatively strict criteria for the diagnosis of unstable angina were used.8' 0 Thus, the conditions of a substantial number of patients progressed to infarction despite intensive therapy. Emerging evidence that transmural myocardial infarction is usually associated with coronary thrombosis35 implies that the occurrence of infarction in patients with unstable angina in many cases is due to thrombosis. Furthermore, a recent study of 1266 men with unstable angina randomly assigned to aspirin or placebo therapy for 12 weeks demonstrated a 51 % reduction in the incidence of death or acute myocardial infarction. 36 Thus, there appears to be a need for a general reappraisal of the value of antiplatelet agents, anticoagulants, '" and fibrinolytic37 38 therapy for the prevention of infarction in patients with unstable angina.
Too few deaths occurred in the study to support any conclusions about the effect of nifedipine compared with conventional therapy on mortality in patients with unstable angina. Furthermore, interpretation of the four deaths that occurred in those who initially received nifedipine is complicated by the fact that two of the four occurred in patients receiving triple therapy (nifedipine, nitrates, and propranolol) and one occurred in a patient on nitrates and propranolol alone.
It is of interest that all of the deaths occurred as a result of a myocardial infarction leading to cardiogenic shock. Nifedipine might be expected to be of benefit in limiting infarct size in these patients, but a study of nifedipine therapy for threatened and acute myocardial infarction conducted in parallel with the present study did not show such a beneficial effect. 39 The lack of benefit in the infarction study could have been due to a delay in initiation of therapy (mean interval from onset of pain to treatment, 4.6 + 0.1 hr), which would not occur in the unstable angina setting. However, the number of patients with infarction in the unstable angina study is far too small to detect a beneficial effect, if present. Hence, neither of the two studies offers direct evidence for or against the continuation of nifedipine therapy in patients with unstable angina whose conditions progress to myocardial infarction.
The findings of this randomized double-blind study support the use of nifedipine alone as an alternative to propranolol and/or nitrates for the initial medical therapy of unstable angina pectoris. In 
